Amassing the Clinical Evidence for Optimized Dyslipidemia Ma - Episode 16
The MD Magazine Peer Exchange “Amassing the Clinical Evidence for Optimized Dyslipidemia Management: Vitamin D, Long-Term Statin Outcomes, and PCSK9 Inhibition” features expert insight and analysis of the latest information on managing hypertension and hyperlipidemia, and in-depth discussion on the use of PCSK9 inhibitors in practice.
This Peer Exchange is moderated by Peter Salgo, MD, professor of medicine and anesthesiology at Columbia University and an associate director of surgical intensive care at the New York-Presbyterian Hospital in New York City.
The panelists are:
While long-term safety data will be needed before any firm conclusions can be made about the safety of PCSK9 inhibitors, their efficacy results may put them in a position to replace statins in the future. Robinson shared the preliminary cardiovascular outcomes data from the PCSK9 safety studies, which showed a reduction in cardiovascular events in the PCSK9 group. These data need to be interpreted with caution, though, according to Ferdinand, because they were retrospectively obtained. Future prospective safety outcomes studies will need to be performed to provide the bigger safety picture.